Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 1
2012 2
2013 1
2014 3
2015 2
2019 1
2020 1
2021 3
2023 1
2024 5
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean michele susani (3 results)?
Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm.
Paolieri F, Sammarco E, Ferrari M, Salfi A, Bonato A, Serafin D, Coccia N, Manfredi F, Zatteri L, Dima G, Carli C, Di Vita R, Oliveri M, Doni L, Galli L, Sisani M, Catalano M, Roviello G, Bloise F. Paolieri F, et al. Among authors: sisani m. Clin Genitourin Cancer. 2024 Aug;22(4):102096. doi: 10.1016/j.clgc.2024.102096. Epub 2024 Apr 15. Clin Genitourin Cancer. 2024. PMID: 38759335 Review.
PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.
Francolini G, Porreca A, Facchini G, Santini D, Bruni A, Simoni N, Trovò M, Osti MF, Fornarini G, Sisani M, Di Cataldo V, Detti B, Garlatti P, Bertini N, Serni S, Minervini A, Livi L. Francolini G, et al. Among authors: sisani m. Med Oncol. 2023 Dec 29;41(1):39. doi: 10.1007/s12032-023-02268-3. Med Oncol. 2023. PMID: 38157111 Clinical Trial.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Clinical Trial.
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients.
Buti S, Olivari A, Masini C, Bimbatti D, Sartori D, Ermacora P, Cattrini C, Vitale MG, Rossi E, Mucciarini C, Rizzo M, Sisani M, Santoni M, Roviello G, Mollica V, Conteduca V, Grillone F, Cinausero M, Prati G, Atzori F, Stellato M, Massari F, Bersanelli M. Buti S, et al. Among authors: sisani m. Ther Adv Urol. 2024 Apr 17;16:17562872241244574. doi: 10.1177/17562872241244574. eCollection 2024 Jan-Dec. Ther Adv Urol. 2024. PMID: 38638242 Free PMC article.
Results of the observational prospective RealFLOT study.
Giommoni E, Lavacchi D, Tirino G, Fornaro L, Iachetta F, Pozzo C, Satolli MA, Spallanzani A, Puzzoni M, Stragliotto S, Sisani M, Formica V, Giovanardi F, Strippoli A, Prisciandaro M, Di Donato S, Pompella L, Pecora I, Romagnani A, Fancelli S, Brugia M, Pillozzi S, De Vita F, Antonuzzo L. Giommoni E, et al. Among authors: sisani m. BMC Cancer. 2021 Oct 8;21(1):1086. doi: 10.1186/s12885-021-08768-7. BMC Cancer. 2021. PMID: 34625033 Free PMC article.
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
Bracarda S, Sisani M, Marrocolo F, Hamzaj A, Del Buono S, Altavilla A. Bracarda S, et al. Among authors: sisani m. Expert Rev Anticancer Ther. 2014 Nov;14(11):1283-94. doi: 10.1586/14737140.2014.965686. Epub 2014 Oct 29. Expert Rev Anticancer Ther. 2014. PMID: 25353258 Review.
Biologic tools to personalize treatment in genitourinary cancers.
Bracarda S, Sisani M, Del Buono S, Ishiwa O, Montagnani F; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Bracarda S, et al. Among authors: sisani m. Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e42-8. doi: 10.1016/j.critrevonc.2010.09.008. Epub 2011 Jan 12. Crit Rev Oncol Hematol. 2012. PMID: 21232974 Review.
20 results